In-depth articles on bacterial adhesion biology, anti-adhesion therapeutics, and microbial pathogenesis.
Urinary tract infections affect 150 million people annually, and uropathogenic E. coli (UPEC) is responsible for over 80% of cases. The initial step in UPEC pathogenesis is FimH-mediated adhesion to mannosylated uroplakin receptors on the bladder epithelium. FimH, the mannose-binding lectin at the tip of type 1 fimbriae, adopts a "catch bond" mechanism: binding strength increases under shear stress from urine flow, ensuring the bacterium resists mechanical clearance.
Structure-based drug design using the crystal structure of the FimH lectin domain (PDB: 1KLF) has yielded alpha-D-mannosides with nanomolar affinity. The lead compound, GC376-M, shows 70% reduction in recurrent UTI in Phase II trials (n=302, p<0.001). Unlike antibiotics, mannosides do not kill bacteria, eliminating selective pressure for resistance. Combination with cranberry proanthocyanidins (which block P fimbriae) shows synergistic effects in mouse models.
Challenges remain: oral bioavailability of mannosides is limited (F=12-18%), requiring prodrug strategies. Additionally, FimH allelic variation across UPEC strains may affect antagonist efficacy. Current research focuses on bivalent mannosides that bridge two FimH binding sites and non-carbohydrate FimH inhibitors with improved pharmacokinetics.
Curli fibers are the major proteinaceous component of the extracellular matrix in E. coli and Salmonella biofilms. Composed of CsgA subunits assembled via the dedicated curli biogenesis pathway (CsgB nucleator, CsgE/F/G secretion apparatus), curli form cross-beta amyloid structures that are remarkably resistant to protease degradation, detergents, and heat.
Beyond their structural role in biofilms, curli fibers are potent activators of the innate immune system. They bind TLR2, activating NF-kB-dependent cytokine production, and trigger the NLRP3 inflammasome, leading to IL-1beta secretion. Cryo-EM structures at 3.2 angstrom resolution reveal that CsgA assembles into a novel five-strand beta-helix, distinct from pathological amyloids like Abeta and alpha-synuclein.
Clinically, curli-producing bacteria cause persistent biofilm infections on catheters and prosthetic devices. Anti-curli strategies include CsgC-based inhibitors that prevent CsgA aggregation (IC50=2.3uM) and engineered bacteriophages expressing DspB that degrade the biofilm matrix. The molecular mimicry between curli and human amyloids also implicates chronic gut infections in autoimmunity, particularly systemic lupus erythematosus.
The rationale for adhesin-based vaccines is compelling: antibodies that block bacterial attachment prevent colonization before infection begins, representing a fundamentally different strategy from toxoid or capsular vaccines. Because anti-adhesin antibodies do not kill bacteria directly, they create minimal selective pressure for resistance, a critical advantage in the era of antimicrobial resistance.
The most advanced adhesin vaccine candidates include: (1) FimCH, a FimH-FimC chaperone complex for E. coli UTI (Phase II, 52% efficacy at 12 months); (2) rBP-Fhb, a recombinant Bordetella pertussis filamentous hemagglutinin for whooping cough (Phase III, non-inferior to acellular pertussis vaccine); and (3) IsdB-ClfA, a bivalent S. aureus vaccine targeting iron-regulated surface protein and clumping factor A (Phase II for surgical prophylaxis).
Key challenges include adhesin structural flexibility (conformational changes upon receptor binding can expose or hide epitopes), redundancy of adhesin systems (bacteria often express multiple adhesins targeting different receptors), and the need for mucosal immunity at sites of colonization. Intranasal and sublingual delivery systems using nanoparticle adjuvants are showing promise in addressing the mucosal immunity challenge.